Replies to post #158770 on Anavex Life Sciences Corp (AVXL)

[MycroftHolmes]

RE: AAIC

Yes, very close to my own assessment. BIIB is singlehandedly trying to keep the amyloid hypothesis alive and there will be alot of attention on it.

The idea of the Sigma Receptor target will hopefully get some good exposure along the way.

I look forward to the genomic data but don’t expect anything earth shattering at this conference for AVXL.

An announcement of U.S. Rett/AD trial starts is likely the biggest news to hope for.

Cheers

Mycroft

[Kentucky123]

"I would not be at all surprised if there is some SP reaction but I would not expect a huge move (beyond 4.2 or below 2.5)

Technically you have a 95% chance of being accurate. A move up to 4.2 would be right at resistance and at the top of the Bollinger bands which contains 95% of the price action of a financial instrument. There is only a 5% chance that it moves outside those parameters. If price moves above 4.2 it will break the three year down trend.

[Amatuer17]

Good assessment. Spot on.
Puts to rest all unrealistic expectations from AAIC

[XenaLives]

Close but no cigar...

I wouldn't want anyone to be disappointed because a "genetic marker" isn't named.

This is the same Phase 2a with the same tiny group and without a placebo to compare. Possibly, the only new data will be that a genetic marker will be named, specifically rather than generally, that was associated with a better outcome. The scientists and clinicians in the audience will be scanning the slides for the placebo comparator and wondering why none was included. The analysts in the room will be checking their watch to see how much longer they need to wait for BIIB's talk.

We are looking for biomarkers not genetic markers. These terms are not synonymous.

Anavex Life Sciences Provides Clinical Programs Update and Reports ...
https://www.anavex.com/anavex-life-sciences-provides-clinical-programs-update-repo...
Feb 7, 2018 - “We believe Anavex is pioneering the inclusion of advanced genomic biomarkers into late-stage CNS precision medicine trials, including our Rett syndrome, ...
Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical ...
https://www.anavex.com/anavex-life-sciences-receives-approval-to-initiate-phase-2-cli...

Jul 9, 2018 - The Company 's trial design for the Phase 2 program in PDD includes genomic, precision medicine-based biomarkers identified from patients previously treated ...
Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial ...
https://www.anavex.com/anavex-life-sciences-reports-fiscal-second-quarter-2018-fina...

May 10, 2018 - “We are looking forward, focusing on executing clinical trials using the inclusion of advanced genomic biomarkers into late-stage CNS precision medicine trials, ...
Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 ...
https://www.anavex.com/anavex-life-sciences-receives-approval-to-initiate-phase-2b-3...

Anavex Life Sciences Provides Clinical Programs ... - GlobeNewswire
https://globenewswire.com/.../Anavex-Life-Sciences-Provides-Clinical-Programs-Upda...
Feb 7, 2018 - “We believe Anavex is pioneering the inclusion of advanced genomic biomarkers into late-stage CNS precision medicine trials, including our Rett syndrome, ...

Anavex Life Sciences Receives Approval to Initiate ... - GlobeNewswire
https://globenewswire.com/.../Anavex-Life-Sciences-Receives-Approval-to-Initiate-Ph...
Jul 9, 2018 - Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ... biomarkers identified from patients previously treated with ANAVEX®2-73...

Google the two terms - it's pretty evident.

"biomarkers anavex"

"genetic markers anavex"

Perspective on future role of biological markers in clinical therapy
trials of Alzheimer’s disease: A long-range point of view beyond 2020
Harald Hampel a,
*, Simone Lista b,
*, Stefan J. Teipel c,d
, Francesco Garaci e,f
,
Robert Nistico` g,h
, Kaj Blennow i
, Henrik Zetterberg i,j
, Lars Bertram k
, Charles Duyckaerts l
,
Hovagim Bakardjian m,n
, Alexander Drzezga o
, Olivier Colliot p,q,r,s,t
, Ste´phane Epelbaum u,v
,
Karl Broich w, Ste´phane Lehe´ ricy n,p,q,r,s
, Alexis Brice p,q,r,s,x
, Zaven S. Khachaturian y
,
Paul S. Aisen z
, Bruno Dubois u,v

http://pubman.mpdl.mpg.de/pubman/item/escidoc:1982964/component/escidoc:1989744/Hampel.pdf

A Precision Medicine Initiative for Alzheimer’s disease:
the road ahead to biomarker-guided integrative disease
modeling.
Harald Hampel, Sid O’bryant, Stanley Durrleman, Erfan Younesi, Katrine
Rojkova, Valentina Escott-Price, Jean-Christophe Corvol, Karl Broich, Bruno
Dubois, Simone Lista

https://hal.inria.fr/hal-01566281/document

[bas2020]

Your supposition is not wrong with regard to AAIC; however, I believe, as in the past, Anavex will continue to compare its results against historical placebo data from past Alz trials, which have be developed over decades of time and is a good comparative measure in assessing the potential of a drug candidate. Only the naysayers will dismiss any reports of good data.